MicroRNAs in heart failure: New targets in disease management

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 480-489

  Elzenaar, I ^a   Pinto, Y M ^a   Van Oort, R J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ELECTROPHYSIOLOGY; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; GENETIC REGULATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

CARDIOMEGALY; ENDOMYOCARDIAL FIBROSIS; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MICRORNAS; MODELS, CARDIOVASCULAR; MOLECULAR TARGETED THERAPY; VENTRICULAR REMODELING;

EID: 84884498546     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.138     Document Type: Review

References (75)

1. Go, A.S. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Ono, K., Kuwabara, Y. & Han, J. MicroRNAs and cardiovascular diseases. FEBS J. 278, 1619-1633 (2011).
3. Topkara, V.K. & Mann, D.L. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc. Drugs Ther. 25, 171-182 (2011).
4. da Costa Martins, P.A. et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118, 1567-1576 (2008).
5. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
6. van Rooij, E. & Olson, E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11, 860-872 (2012).
7. Ota, H. et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 153, 575-589 (2013).
8. Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855-862 (1993). (Pubitemid 24014543)
9. Kozomara, A. & Grifths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39, D152-D157 (2011).
10. Sayed, D. & Abdellatif, M. MicroRNAs in development and disease. Physiol. Rev. 91, 827-887 (2011).
11. van Rooij, E. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 103, 18255-18260 (2006). (Pubitemid 44871645)
12. Thum, T. et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267 (2007). (Pubitemid 47196561)
13. Sayed, D., Hong, C., Chen, I.Y., Lypowy, J. & Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100, 416-424 (2007).
14. Ikeda, S. et al. Altered microRNA expression in human heart disease. Physiol. Genomics 31, 367-373 (2007). (Pubitemid 350127777)
15. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fbrosis. Proc. Natl. Acad. Sci. USA 105, 13027-13032 (2008).
16. Sucharov, C., Bristow, M.R. & Port, J.D. miRNA expression in the failing human heart: functional correlates. J. Mol. Cell. Cardiol. 45, 185-192 (2008).
17. Cheng, Y. et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am. J. Pathol. 170, 1831-1840 (2007). (Pubitemid 47339258)
18. Tatsuguchi, M. et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 42, 1137-1141 (2007). (Pubitemid 46829201)
19. Matkovich, S.J. et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119, 1263-1271 (2009).
20. Naga Prasad, S.V. et al. Unique microRNA profle in end-stage heart failure indicates alterations in specifc cardiovascular signaling networks. J. Biol. Chem. 284, 27487-27499 (2009).
21. Leptidis, S. et al. A deep sequencing approach to uncover the miRNOME in the human heart. PLoS ONE 8, e57800 (2013).
22. Da Costa Martins, P.A. & De Windt, L.J. MicroRNAs in control of cardiac hypertrophy. Cardiovasc. Res. 93, 563-572 (2012).
23. Oliveira-Carvalho, V., Silva, M.M., Guimarães, G.V., Bacal, F. & Bocchi, E.A. MicroRNAs: new players in heart failure. Mol. Biol. Rep. 40, 2663-2670 (2012).
24. Gladka, M.M., da Costa Martins, P.A. & De Windt, L.J. Small changes can make a big diference-microRNA regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 52, 74-82 (2012).
25. van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J. & Olson, E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007). (Pubitemid 46683138)
26. Callis, T.E. et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772-2786 (2009).
27. Tardif, J.C., Hewett, T.E., Factor, S.M., Vikstrom, K.L., Robbins, J. & Leinwand, L.A. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional efects. Am. J. Physiol. Heart Circ. Physiol. 278, H412-H419 (2000). (Pubitemid 30131239)
28. Lin, Z., Murtaza, I., Wang, K., Jiao, J., Gao, J. & Li, P.F. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 106, 12103-12108 (2009).
29. Wang, J. et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res. 22, 516-527 (2012).
30. da Costa Martins, P.A. et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplifcation loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12, 1220-1227 (2010).
31. Ucar, A. et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012).
32. Huang, Z.P. et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 112, 1234-1243 (2013).
33. Gurha, P. et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 125, 2751-2761 (2012).
34. Carè, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13, 613-618 (2007). (Pubitemid 46828487)
35. Ikeda, S. et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 29, 2193-2204 (2009).
36. Karakikes, I. et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc. 2, e000078 (2013).
37. Li, Q. et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinflin-1 to provoke cardiac hypertrophy. J. Cell. Sci. 123, 2444-2452 (2010).
38. Elia, L. et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120, 2377-2385 (2009).
39. Dong, D.L. et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 55, 946-952 (2010).
40. Li, Q., Lin, X., Yang, X. & Chang, J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am. J. Physiol. Heart Circ. Physiol. 298, H1340-H1347 (2010).
41. Liu, N. et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22, 3242-3254 (2008).
42. Matkovich, S.J. et al. MicroRNA-133a protects against myocardial fbrosis and modulates electrical repolarization without afecting hypertrophy in pressure-overloaded adult hearts. Circ. Res. 106, 166-175 (2010).
43. Wang, K., Long, B., Zhou, J. & Li, P.F. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J. Biol. Chem. 285, 11903-11912 (2010).
44. Ganesan, J. et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127, 2097-2106 (2013).
45. Nagalingam, R.S., Sundaresan, N.R., Gupta, M.P., Geenen, D.L., Solaro, R.J. & Gupta, M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J. Biol. Chem. 288, 11216-11232 (2013).
46. Knezevic, I. et al. A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J. Biol. Chem. 287, 12913-12926 (2012).
47. Creemers, E.E. & Pinto, Y.M. Molecular mechanisms that control interstitial fbrosis in the pressure-overloaded heart. Cardiovasc. Res. 89, 265-272 (2011).
48. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fbroblasts. Nature 456, 980-984 (2008).
49. Roy, S. et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fbroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82, 21-29 (2009).
50. Patrick, D.M. et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120, 3912-3916 (2010).
51. Tijsen, A.J., Pinto, Y.M. & Creemers, E.E. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc. Res. 93, 573-582 (2012).
52. Dawson, K. et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fbrillation. Circulation 127, 1466-75, 1475e1 (2013).
53. Duisters, R.F. et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104, 170-178, 6 pp following 178 (2009).
54. Castoldi, G. et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fbrosis in angiotensin II-dependent hypertension. J. Cell. Physiol. 227, 850-856 (2012).
55. Pan, Z. et al. MicroRNA-101 inhibited postinfarct cardiac fbrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-ß1 pathway. Circulation 126, 840-850 (2012).
56. Wang, J. et al. MicroRNA-24 regulates cardiac fbrosis after myocardial infarction. J. Cell. Mol. Med. 16, 2150-2160 (2012).
57. Qian, L., Van Laake, L.W., Huang, Y., Liu, S., Wendland, M.F. & Srivastava, D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208, 549-560 (2011).
58. Fiedler, J. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720-730 (2011).
59. Zhao, Y. et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129, 303-317 (2007). (Pubitemid 46574975)
60. Yang, B. et al. The muscle-specifc microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486-491 (2007). (Pubitemid 46559834)
61. Luo, X. et al. MicroRNA-26 governs profbrillatory inward-rectifer potassium current changes in atrial fbrillation. J. Clin. Invest. 123, 1939-1951 (2013).
62. Lu, Y. et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fbrillation. Circulation 122, 2378-2387 (2010).
63. Terentyev, D. et al. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ. Res. 104, 514-521 (2009).
64. Respress, J.L. et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ. Res. 110, 1474-1483 (2012).
65. van Oort, R.J. et al. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 122, 2669-2679 (2010).
66. Belevych, A.E. et al. MicroRNA-1 and-133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS ONE 6, e28324 (2011).
67. Ali, R. et al. miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. J. Mol. Cell. Cardiol. 52, 1027-1037 (2012).
68. Tritsch, E. et al. An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart. Cardiovasc. Res. 98, 372-380 (2013).
69. + overload and cell death. J. Clin. Invest. 122, 1222-1232 (2012).
70. Li, R.C. et al. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ. Res. 112, 601-605 (2013).
71. Xu, M. et al. Mir-24 regulates junctophilin-2 expression in cardiomyocytes. Circ. Res. 111, 837-841 (2012).
72. van Oort, R.J. et al. Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice. Circulation 123, 979-988 (2011).
73. Latronico, M.V. & Condorelli, G. Therapeutic use of microRNAs in myocardial diseases. Curr. Heart Fail. Rep. 8, 193-197 (2011).
74. Tijsen, A.J., Pinto, Y.M. & Creemers, E.E. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 303, H1085-H1095 (2012).
75. Creemers, E.E., Tijsen, A.J. & Pinto, Y.M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 110, 483-495 (2012).